Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective?

about

A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs.BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer.

P2860

Q36814377-D99577A1-478E-4085-A5B0-7B9982E0FCBA Q55080436-E370B50C-4C5F-4077-A859-1CDE9761C4D3

P2860

Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective?

Item

http://www.wikidata.org/entity/Q46755119

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Adjuvant fluorouracil, epirubi ...... cancer: is it cost-effective?

@en

Adjuvant fluorouracil, epirubi ...... cancer: is it cost-effective?

@nl

type

Item

label

Adjuvant fluorouracil, epirubi ...... cancer: is it cost-effective?

@en

Adjuvant fluorouracil, epirubi ...... cancer: is it cost-effective?

@nl

prefLabel

Adjuvant fluorouracil, epirubi ...... cancer: is it cost-effective?

@en

Adjuvant fluorouracil, epirubi ...... cancer: is it cost-effective?

@nl

P1476

Adjuvant fluorouracil, epirubi ...... cancer: is it cost-effective?

@en

P2093

Jan Norum

http://www.w3.org/2001/XMLSchema#string

Mari Holtmon

http://www.w3.org/2001/XMLSchema#string

P2860

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer--is it cost-effective?

The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions.

A systematic overview of chemotherapy effects in breast cancer.

Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis.

Adjuvant therapy for breast cancer--results from the USA consensus conference.

The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial.

Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?

Impact of two different dose-intensity chemotherapy regimens on psychological distress in early breast cancer patients.

Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.

P304

735-741

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1080/02841860500247503

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7539549

http://www.w3.org/2001/XMLSchema#string

P698

16227165

http://www.w3.org/2001/XMLSchema#string

Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective?

about

P2860

P2860

Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698